Weigang Meng

Weigang’s experience at and prior to joining Latham includes advising:

• Shenzhen Kinwong Electronic, a globally recognized printed circuit board manufacturer, on its HK$5.1 billion IPO on HKEX
• The underwriters on the HK$1.76 billion IPO of Crealights Technology, an optical interconnection products provider, on HKEX
• The underwriters on the HK$1.64 billion IPO of EpiWorld International, a global leader in the silicon carbide epitaxy industry, on HKEX
• The underwriters on the HK$1.8 billion Ch.18C IPO of Huayan Robotics, a collaborative robotics company, on HKEX
• The underwriters on the HK$5.2 billion IPO of Huaqin, an A-share listed smart product platform integrating AI, IoT, big data, and communication technologies, on HKEX
• The underwriters on the HK$1.4 billion Ch.18C IPO of CiDi, a provider of intelligent driving products for commercial vehicles in China, on HKEX
• The underwriters on the HK$1.85 billion IPO of CaoCao, a leading ride-hailing platform in China, on HKEX. This transaction was recognized as a Remarkable Deal of the Year – China by LegalOne 2025
• The underwriters on the HK$1.4 billion IPO of Drinda, a leading specialized manufacturer of photovoltaic cells, on HKEX
• J&T Express, a global logistics service provider, on its HK$3.9 billion IPO on HKEX. This multi-award winning deal was named Equity Market Deal of the Year at the ALB Hong Kong Law Awards 2024, Equity Market Deal of the Year – Midsize at the ALB China Law Awards 2024, Best IPO: China-Offshore at the FinanceAsia Achievement Awards 2024, Equity Market Deal of the Year at the ALB SE Asia Law Awards 2024, Equity Deal of the Year at the IFLR Asia-Pacific Awards 2024, and one of the Equity Capital Markets Deals of the Year by China Business Law Journal’s Deals of the Year Awards 2023
• CaoCao on its placing of new shares priced at HK$32.46 per share, raising net proceeds of approximately HK$383 million
• The joint placing agent on the top-up placing of shares of Ascentage Pharma Group International, a global, commercial-stage biopharmaceutical company
• Yonghe Medical Group Co., Ltd. on its US$192 million IPO on HKEX
• The underwriters on the approximately US$1.67 billion secondary listing of GDS Holdings Limited on HKEX
• Acotec Scientific Holdings Ltd. on its US$210 million IPO on HKEX
• Warburg Pincus as a major shareholder in ESR Cayman Limited’s US$1.6 billion listing on HKEX
• CITIC Private Equity Funds Management Co., Ltd. as the controlling shareholder in Manpower Group Inc.’s US$65 million listing on NYSE
• China Zheshang Bank Co., Ltd. on its US$1.75 billion H share listing
• China Huarong Asset Management Co., Ltd. on its US$2.3 billion H share listing
• The underwriters on Greentown Management Holdings Co., Ltd.’s US$154 million spinoff and listing on HKEX
• Shanghai Dongzheng Auto Finance Co., Ltd. on its US$208 million H share spinoff and listing
• The underwriters on Maoyan Entertainment’s US$250 million listing on HKEX
• Chengdu Expressway Co., Ltd. on its US$128 million H share listing
• Mobvista on its US$171 million listing on HKEX
• Qingdao Port International Co., Ltd. on its US$840 million H share placement
• The underwriters on Inner Mongolia Energy Engineering Co., Ltd.’s US$150 million H share listing
• The underwriters on Guangdong Kanghua Healthcare Co., Ltd.’s US$114 million H share listing
• Beijing Jingneng Clean Energy Co., Ltd. on its US$162 million H share placement
• The underwriters on China Energy Engineering Corporation Limited’s US$1.96 billion H share listing
• The underwriters on Dalian Wanda Commercial Properties Co., Ltd.’s US$4.2 billion H share listing

Public Company Representation

Weigang’s Hong Kong-listed company clients have included:

• Kuaishou Technology
• Greentown Management Holdings Co., Ltd.
• Acotec Scientific Holdings Ltd.
• Agricultural Bank of China
• Dalian Wanda Commercial Properties Co., Ltd.
• Qingdao Port International Co., Ltd.
• Beijing Jingneng Clean Energy Co., Ltd.